Rapport Therapeutics, Inc. Common Stock (RAPP)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $1.55B
Last updated: Nov 17, 2026 at 11:05 AM ET
Rapport Therapeutics, Inc. Common Stock (RAPP) Competitors
The companies most similar to Rapport Therapeutics, Inc. Common Stock are Structure Therapeutics Inc. American Depositary Shares (GPCR), Sarepta Therapeutics (SRPT) and Recursion Pharmaceuticals (RXRX). By market cap, Rapport Therapeutics, Inc. Common Stock ranks 6th of the 13 companies on this page; Denali Therapeutics (DNLI) is the largest at $3.00B.
Peer Comparison
RAPP's revenue growth of 0.0% is in line with the peer median. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| Rapport Therapeutics, Inc. Common Stock (RAPP) | $1.55B | N/A | 59.3x | 0.0% | N/A | 0.0% | 0.00% |
| Structure Therapeutics Inc. American Depositary Shares (GPCR) | $1.43B | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Sarepta Therapeutics Inc (SRPT) | $1.72B | N/A | 0.8x | -5.9% | -3.2% | -4.5% | 0.00% |
| Recursion Pharmaceuticals Inc (RXRX) | $1.99B | N/A | 23.1x | 0.0% | -51.8% | 258.5% | 0.00% |
| Alto Neuroscience, Inc. (ANRO) | $1.18B | N/A | N/A | 0.0% | -23.5% | 0.0% | 0.00% |
| Silence Therapeutics PLC (SLN) | $1.23B | N/A | 882.5x | 0.0% | N/A | 197.2% | 0.00% |
| Tyra Biosciences Inc (TYRA) | $1.38B | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Taysha Gene Therapies Inc (TSHA) | $1.34B | N/A | 300.6x | 0.0% | -32.8% | 171.3% | 0.00% |
| Mineralys Therapeutics, Inc. Common Stock (MLYS) | $1.36B | N/A | N/A | 0.0% | -51.1% | 0.0% | 0.00% |
| Trevi Therapeutics Inc (TRVI) | $1.95B | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Theravance Biopharma Inc (TBPH) | $884.18M | 95.1x | 8.4x | 51.6% | N/A | -20.9% | 0.00% |
| Denali Therapeutics Inc (DNLI) | $3.00B | N/A | 159.3x | 0.0% | N/A | -100.0% | 0.00% |
| Beam Therapeutics Inc (BEAM) | $2.36B | N/A | 15.0x | -73.9% | -29.7% | -96.8% | 0.00% |
| Peer median | $1.41B | 95.1x | 23.1x | 0.0% | -31.2% | 0.0% | 0.00% |
Similar Companies
These are the 12 companies most similar to Rapport Therapeutics, Inc. Common Stock, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| Structure Therapeutics Inc. American Depositary Shares (GPCR) | Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic... | GPCR competitors |
| Sarepta Therapeutics Inc (SRPT) | Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapies, gene therapy... | SRPT competitors |
| Recursion Pharmaceuticals Inc (RXRX) | Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that decodes biology by integrating technological innovations in biology, chemistry... | RXRX competitors |
| Alto Neuroscience, Inc. (ANRO) | Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company that engages in the psychiatry drug development business. | ANRO competitors |
| Silence Therapeutics PLC (SLN) | Silence Therapeutics plc, a biotechnology company, is focused on the discovery and development of new ribonucleic acid (RNA) therapies in hematology... | SLN competitors |
| Tyra Biosciences Inc (TYRA) | Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and improve outcomes... | TYRA competitors |
| Taysha Gene Therapies Inc (TSHA) | Taysha Gene Therapies, Inc., a gene therapy company, focuses on the development and commercialization of adeno-associated virus-based gene therapies... | TSHA competitors |
| Mineralys Therapeutics, Inc. Common Stock (MLYS) | Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular... | MLYS competitors |
| Trevi Therapeutics Inc (TRVI) | Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on the development and commercialization of Haduvio to treat serious... | TRVI competitors |
| Theravance Biopharma Inc (TBPH) | Theravance Biopharma, Inc., a diversified biopharmaceutical company, discovers, develops, and markets organ-selective drugs in the United States, Europe... | |
| Denali Therapeutics Inc (DNLI) | Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. | DNLI competitors |
| Beam Therapeutics Inc (BEAM) | Beam Therapeutics Inc., a biotechnology company, develops precision genetic drugs for patients with serious illnesses in the United States. | BEAM competitors |
Frequently Asked Questions About RAPP
Who are Rapport Therapeutics, Inc. Common Stock's main competitors?
The companies most similar to Rapport Therapeutics, Inc. Common Stock include Structure Therapeutics Inc. American Depositary Shares (GPCR), Sarepta Therapeutics (SRPT), Recursion Pharmaceuticals (RXRX), Alto Neuroscience (ANRO) and Silence Therapeutics (SLN), listed from the closest match.
Who is Rapport Therapeutics, Inc. Common Stock's biggest competitor?
Denali Therapeutics (DNLI) is the largest of the similar companies at $3.00B; Structure Therapeutics Inc. American Depositary Shares (GPCR) is the closest match by business profile, size, sector and industry.
How does RAPP stock compare with its competitors?
RAPP's P/S is 59.3x against a peer median of 23.1x; its net margin is 0.0% against a peer median of 0.0%.
Which of Rapport Therapeutics, Inc. Common Stock's competitors pays a higher dividend?
Rapport Therapeutics, Inc. Common Stock pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is Rapport Therapeutics, Inc. Common Stock bigger than its competitors?
No. Rapport Therapeutics, Inc. Common Stock is 6th by market cap among the 13 companies on this page; the largest is Denali Therapeutics (DNLI) at $3.00B.
RAPP pages: Overview, Earnings, Forecast, Competitors